Urology
Volume 75, Issue 5 , Pages 1149-1155, May 2010

Efficacy and Tolerability of Fesoterodine in Men With Overactive Bladder: A Pooled Analysis of 2 Phase III Studies

  • Sender Herschorn

      Affiliations

    • Sunnybrook Health Sciences Centre, Division of Urology, Toronto, Ontario, Canada
    • Corresponding Author InformationReprint requests: Sender Herschorn, M.D., Sunnybrook Health Sciences Centre, 2075 Bayview Ave, Toronto, ON M4N3M5, Canada
    • ,
  • J. Stephen Jones

      Affiliations

    • Glickman Urological & Kidney Institute, Cleveland Clinic, Beachwood, Ohio
    • ,
  • Matthias Oelke

      Affiliations

    • Hannover Medical School, Department of Urology, Hannover, Germany
    • ,
  • Scott MacDiarmid

      Affiliations

    • Alliance Urology Specialists, Greensboro, North Carolina
    • ,
  • Joseph T. Wang

      Affiliations

    • Pfizer Inc, New York, New York
    • ,
  • Zhonghong Guan

      Affiliations

    • Pfizer Inc, New York, New York

Received 10 June 2009; accepted 1 September 2009. published online 16 November 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 This study was funded by Schwarz BioSciences GmbH and Pfizer Inc.

PII: S0090-4295(09)02529-1

doi:10.1016/j.urology.2009.09.007

Urology
Volume 75, Issue 5 , Pages 1149-1155, May 2010

Article Tools

* Image Usage & Resolution